A new market beckons for Alzheimer’s blood tests

Success in clinical trials of drugs for Alzheimer’s disease seems to hinge in large part on picking the right patients. Recent positive – just – data on Lilly’s anti-tau project donanemab came from a trial that excluded patients with high tau levels, and dona’s ongoing pivotal trial is using similar enrolment criteria.